New cancer drugs hit US market first
A new survey shows that there is a huge difference in how soon patients in the US gain access to novel cancer medicine compared with their European peers.
BY BENJAMIN WERNER CHRISTENSEN
Six months. That is, on average, how much longer it takes for the European Medicines Agency, EMA, to approve new drugs to combat cancer compared with its US counterpart, FDA, according to a new survey.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
EMA wants clear guidelines for genomic biomarkers
For abonnenter
Pilot project: early access in the EU
For abonnenter
